نتایج جستجو برای: ambrisentan

تعداد نتایج: 197  

2017
Cihangir Kaymaz Bülent Mutlu M. Serdar Küçükoğlu Barış Kaya Bahri Akdeniz Burçak Kılıçkıran Avcı Enbiya Aksakal Mehmet Akbulut Zehra Atılgan Arıtürk Sümeyye Güllülü Gülten Aydoğdu Taçoy Meral Kayıkçıoğlu Sanem Nalbantgil Cihan Örem Hatice Betül Erer Murat Yüce Necip Ermiş Omaç Tüfekçioğlu Mesut Demir Mehmet Birhan Yılmaz Mehmet Güngör Kaya Hakan Kültürsay Zeki Öngen Lale Tokgözoğlu

OBJECTIVE The present study was designed to evaluate the characteristics of pulmonary hypertension (PH) and adult cardiology practice patterns for PH in our country. METHODS We evaluated preliminary survey data of 1501 patients with PH (females, 69%; age, 44.8±5.45) from 20 adult cardiology centers (AdCCs). RESULTS The average experience of AdCCs in diagnosing and treating patients with PH ...

2006
Anthony P. Davenport Kelly A. Hyndman Neeraj Dhaun Christopher Southan Donald E. Kohan Jennifer S. Pollock David M. Pollock David J. Webb Janet J. Maguire

The endothelins comprise three structurally similar 21-amino acid peptides. Endothelin-1 and -2 activate two G-protein coupled receptors, ETA and ETB, with equal affinity, whereas endothelin-3 has a lower affinity for the ETA subtype. Genes encoding the peptides are present only among vertebrates. The ligand-receptor signaling pathway is a vertebrate innovation and may reflect the evolution of ...

Journal: :Revista espanola de cardiologia 2015
Carlos G Santos-Gallego Juan José Badimón

Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary vascular resistance (PVR) that causes right ventricular (RV) failure and premature death. This hypertensive condition leads to precapillary pulmonary hypertension, defined as a mean pulmonary artery pressure (mPAP) 25 mmHg, pulmonary capillary wedge pressure 15 mmHg, and PVR > 3 Wood units at rest. The...

2014
J J Maguire A P Davenport

Since the discovery of endothelin (ET)-1 in 1988, the main components of the signalling pathway have become established, comprising three structurally similar endogenous 21-amino acid peptides, ET-1, ET-2 and ET-3, that activate two GPCRs, ETA and ETB . Our aim in this review is to highlight the recent progress in ET research. The ET-like domain peptide, corresponding to prepro-ET-193-166 , has...

Journal: :BMJ case reports 2015
Saraschandra Vallabhajosyula Pranathi Rao Sundaragiri

To cite: Vallabhajosyula S, Sundaragiri PR. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2014209187 DESCRIPTION A 33-year-old Caucasian woman with Class 1 idiopathic pulmonary arterial hypertension (PAH) managed on tadalafil, ambrisentan, treprostinil, digoxin and diuretics presented with progressive dyspnoea and orthopnoea since 2 weeks. Cardiac examination re...

Journal: :The Journal of pharmacology and experimental therapeutics 2017
Magali Vercauteren Frederic Trensz Anne Pasquali Christophe Cattaneo Daniel S Strasser Patrick Hess Marc Iglarz Martine Clozel

Endothelin (ET) receptor antagonists have been associated with fluid retention. It has been suggested that, of the two endothelin receptor subtypes, ETB receptors should not be blocked, because of their involvement in natriuresis and diuresis. Surprisingly, clinical data suggest that ETA-selective antagonists pose a greater risk of fluid overload than dual antagonists. The purpose of this study...

2017
Avraham Sofer Michael J. Ryan Ryan J. Tedford Joel A. Wirth Wassim H. Fares

Pulmonary arterial hypertension (PAH) is a progressive potentially fatal disease. Multiple pharmacologic options are now available, which facilitated transitions between different therapeutic options, although the evidence for such transitions has not been well described. We sought to review the evidence supporting the safety and/or efficacy of transitioning between PAH-specific medications. We...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید